Adenosine regulates tissue factor expression on endothelial cells

Thrombosis Research

Volumn 91, Issue 2, 1998, Pages 57-64

  Deguchi, Hiroshi ^a   Takeya, Hiroyuki ^a   Urano, Hajime ^a   Gabazza, Esteban C ^a   Zhou, Hong ^a   Suzuki, Koji ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenosine; Endothelial cell; Thrombin; Tissue factor

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 6 N [2 (4 AMINOPHENYL)ETHYL]ADENOSINE; 8 (2 AMINO 4 CHLOROPHENYL) 1,3 DIPROPYLXANTHINE; 8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE; ADENOSINE RECEPTOR BLOCKING AGENT; PHORBOL 12 ACETATE 13 MYRISTATE; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY MECHANISM;

ADENOSINE; CARDIOVASCULAR AGENTS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HEMOSTATICS; HUMANS; INFANT, NEWBORN; RECEPTORS, PURINERGIC P1; TETRADECANOYLPHORBOL ACETATE; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS; XANTHINES;

EID: 0032528307     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00045-0     Document Type: Article

References (33)

1. Engler R. Adenosine: The signal of life? Circulation 1991;84:951-4.
2. Ely S, Berne R. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85: 893-904.
3. Downey JM, Liu GS, Thornton JD. Adenosine and the anti-infarct effects of preconditioning. Cardiovasc Res 1993;27:3-8.
4. Kitakaze M, Hori M, Sato H, Takashima S, Inoue M, Kitakaze A, Kamada T. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res 1991; 69:1402-8.
5. Sajjadi F, Takabayashi K, Foster A, Domingo R, Firestein G. Inhibition of TNF-a expression by adenosine: Role of A3 adenosine receptors. J Immunol 1996;156:3435-42.
6. Felsch A, Stocker K, Borchard U. Phorbol ester-stimulated adherence of neutrophils to endothelial cell is reduced by adenosine A2 receptor agonists. J Immunol 1995;155:333-8.
7. Archipoff G, Beretz A, Freyssinet JM, Soyer CK, Brisson C, Cazenave JP. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumor necrosis factor, thrombin or phorbol ester. Biochem J 1991;273:679-84.
8. Galdal KS, Lyberg T, Evensen SA, Nilsen E, Prydz H. Thrombin induces thromboplastin synthesis in cultured vascular endothelial cells. Thromb Haemost 1985;54:373-6.
9. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989;264:20705-13.
10. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane bound cofactor for thrombincatalyzed activation of protein C. J Biol Chem 1982;257:859-64.
11. Miller CL, Graziano C, Lim RC, Chin M. Generation of tissue factor by patient monocytes: Correlation to thromboembolic complications. Thromb Haemost 1981;46:489-95.
12. Okada Y, Copeland B, Fitridge R, Koziol J, del Zoppo G. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994;25:1847-54.
13. Golino P, Ragni M, Cirillo P, Avvedimento V, Feliciello A, Esposito N, Scognamiglio A, Trimarco B, Iaccarino G, Condorelli M, Chiariello M, Ambrosio G. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nature Med 1996;2: 35-40.
14. Callander N, Varki N, Rao L. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-201.
15. Herbert JM, Savi P, Laplace MC, Lale A. IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett 1992; 310:31-3.
16. Martin NB, Jamieson A, Tuffin DP. The effect of interleukin-4 on tumor necrosis factor-alpha induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. Thromb Haemost 1993;70:1037-42.
17. Herbert JM, Savi P, Laplace MC, Lale A, Dol F, Dumas A, Labit C, Minty A. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett 1993;328:268-70.
18. Ishii H, Horie S, Kizaki K, Kazama M. Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood 1992; 80:2556-62.
19. Archipoff G, Beretz A, Bartha K, Brisson C, de la Salle C, Froget-Leon C, Klein-Soyer C, Cazenave JP. Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities. Br J Pharmacol 1993;109:18-28.
20. Deguchi H, Takeya H, Wada H, Gabazza E, Hayashi N, Urano H, Suzuki K. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood 1997;90:2345-56.
21. Ren H, Stiles G. Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. J Biol Chem 1994;269: 3104-10.
22. Salvatore C, Jacobson M, Taylor H, Linden J, Johnson R. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 1993;90:10365-9.
23. Iwamoto T, Umemura S, Toya Y, Uchibori T, Kogi K, Takagi N, Ishii M. Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Com 1994;199:905-10.
24. Maggirwar SB, Dhanraj DN, Somani SM, Ramkumar V. Adenosine acts as an endogenous activator of the cellular antioxidant defence system. Bichem Biophys Res Commun 1994;208:508-15.
25. Gurden M, Coates J, Ellis F, Evans B, Foster M, Hornby E, Kennedy I, Martin D, Strong P, Vardey C, Wheeldon A. Functional characterization of three adenosine receptor types. Br J Pharmacol 1993;109:693-8.
26. Lohse M, Klotz K-N Schwabe U, Cristalli G, Vittori S, Grifantini M. 2-chloro-N6-cyclopentyladenosine: A highly selective agonist at A1 adenosine receptors. Naunyn-Schmiedebergs Arch Phamacol 1991;337:687.
27. Chovan J, Zane P, Greenberg G. Automated-extraction, high performance liquid Chromatographic method and pharmacokinetics in rats of a highly selective adenosine agonist, CGS 21680. J Chromatogr 1992;578:77-83.
28. Collis M, Hourani S. Adenosine receptor subtypes. TIPS 1993;14:360-6.
29. Ramkumar V, Stiles G, Beaven M, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993; 268:16887-90.
30. Ness S, Herzog V, Becker F, Bock M, Rosiers D, Gerlach E. The coronary endothelium is a highly active, metabolic barrier for adenosine. Basic Res Cardiol 1985;80:515-29.
31. Sexl V, Mancusi G, Holler C, Gloria-Maercker E, Schutz W, Freissmuth M. Stimulation of the mitogen-activated protein kinase via the A2a-adenosine receptor in primary human endotheilal cells. J Biol Chem 1997;272:5792-9.
32. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85:3005-20.
33. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715-22.